Home › NDC Lookup › RxCUI directory › RxCUI 197452

Cefprozil 250 MG Oral Tablet — RxCUI 197452

RxNorm drug concept · Semantic clinical drug
RxCUI 197452 Semantic clinical drug · SCD ● Current RxNorm concept 12 FDA products 19 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI197452
Official nameCefprozil 250 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped12
Package NDCs mapped19
Reported Medicaid activity (SDUD)12,609 prescriptions · 33 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Cefprozil: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It’s an antibiotic for mild to moderate bacterial infections of the throat, ears, sinuses, bronchitis and skin. It won’t help colds or flu, which are viral.
  • Take it by mouth, as a tablet or a liquid, once or twice a day as prescribed. Most courses run about 10 days. Strep infections need at least 10 days. Food doesn’t change how much y...
  • The most common are nausea, diarrhea, vomiting and belly pain. Most people tolerate it well.
  • Call right away for signs of a severe allergic reaction, and stop the drug. Also call for severe or lasting diarrhea, even weeks after you finish.
📖 Read our full Cefprozil guide →

🕸️ Concept Web — How Cefprozil 250 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Cefprozil 250 MG Oral Tablet RxCUI 197452

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Cefprozil 19552
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cefprozil Oral Tablet 371336
    • Cefprozil Oral Product 1161217
    • Cefprozil Pill 1161218
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Cefprozil 250 MG 315598

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Cefprozil 250 MG SCDC · 315598
  • Cefprozil Oral Tablet SCDF · 371336
  • Cefprozil Oral Product SCDG · 1161217
  • Cefprozil Pill SCDG · 1161218

📦 FDA Products & Package NDCs

12 products · 19 package NDCs
19 package NDCs map to RxCUI 197452 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00093-1077-01 100 TABLET, FILM COATED in 1 BOTTLE (0093-1077-01) Cefprozil Teva Pharmaceuticals USA, Inc. 2005-12-23
00093-1078-53 50 TABLET, FILM COATED in 1 BOTTLE (0093-1078-53) Cefprozil Teva Pharmaceuticals USA, Inc. 2005-12-23
16714-0398-01 100 TABLET, FILM COATED in 1 BOTTLE (16714-398-01) Cefprozil NorthStar Rx LLC 2007-05-24
16714-0399-01 50 TABLET, FILM COATED in 1 BOTTLE (16714-399-01) Cefprozil NorthStar Rx LLC 2007-05-24
57237-0036-01 100 TABLET, FILM COATED in 1 BOTTLE (57237-036-01) Cefprozil Rising Pharma Holdings, Inc. 2007-05-24
57237-0037-01 100 TABLET, FILM COATED in 1 BOTTLE (57237-037-01) Cefprozil Rising Pharma Holdings, Inc. 2007-05-24
57237-0037-50 50 TABLET, FILM COATED in 1 BOTTLE (57237-037-50) Cefprozil Rising Pharma Holdings, Inc. 2007-05-24
65862-0068-01 100 TABLET, FILM COATED in 1 BOTTLE (65862-068-01) Cefprozil Aurobindo Pharma Limited 2007-05-24
65862-0068-05 500 TABLET, FILM COATED in 1 BOTTLE (65862-068-05) Cefprozil Aurobindo Pharma Limited 2007-05-24
65862-0068-30 30 TABLET, FILM COATED in 1 BOTTLE (65862-068-30) Cefprozil Aurobindo Pharma Limited 2007-05-24
65862-0068-50 50 TABLET, FILM COATED in 1 BOTTLE (65862-068-50) Cefprozil Aurobindo Pharma Limited 2007-05-24
65862-0069-01 100 TABLET, FILM COATED in 1 BOTTLE (65862-069-01) Cefprozil Aurobindo Pharma Limited 2007-05-24
65862-0069-05 500 TABLET, FILM COATED in 1 BOTTLE (65862-069-05) Cefprozil Aurobindo Pharma Limited 2007-05-24
65862-0069-30 30 TABLET, FILM COATED in 1 BOTTLE (65862-069-30) Cefprozil Aurobindo Pharma Limited 2007-05-24
65862-0069-50 50 TABLET, FILM COATED in 1 BOTTLE (65862-069-50) Cefprozil Aurobindo Pharma Limited 2007-05-24
67877-0243-50 50 TABLET, FILM COATED in 1 BOTTLE (67877-243-50) Cefprozil Ascend Laboratories, LLC 2025-01-20
67877-0244-01 100 TABLET, FILM COATED in 1 BOTTLE (67877-244-01) Cefprozil Ascend Laboratories, LLC 2025-01-20
68180-0403-01 100 TABLET in 1 BOTTLE (68180-403-01) CEFPROZIL Lupin Pharmaceuticals, Inc. 2005-12-01
68180-0404-01 50 TABLET in 1 BOTTLE (68180-404-01) CEFPROZIL Lupin Pharmaceuticals, Inc. 2005-12-01
Observed labelers: Aurobindo Pharma Limited (8) · Rising Pharma Holdings, Inc. (3) · Ascend Laboratories, LLC (2) · Lupin Pharmaceuticals, Inc. (2) · NorthStar Rx LLC (2) · Teva Pharmaceuticals USA, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.